Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q5BJH7
UPID:
YIF1B_HUMAN
Alternative names:
YIP1-interacting factor homolog B
Alternative UPACC:
Q5BJH7; H7BXS8; Q5JPC2; Q8WY70; Q96C02; Q96IC4
Background:
Protein YIF1B, also known as YIP1-interacting factor homolog B, plays a crucial role in cellular transport mechanisms, specifically in the endoplasmic reticulum to Golgi vesicle-mediated transport. It is instrumental in maintaining the proper organization of the endoplasmic reticulum and the Golgi apparatus. Furthermore, YIF1B is vital for the targeting of neuronal dendrites receptors such as HTR1A and is implicated in the assembly of primary cilium and sperm flagellum, highlighting its significance in cellular structure and signaling.
Therapeutic significance:
YIF1B's association with Kaya-Barakat-Masson syndrome, a neurodevelopmental disorder characterized by a spectrum of impairments including intellectual development and motor coordination, underscores its therapeutic significance. Understanding the role of Protein YIF1B could open doors to potential therapeutic strategies for treating or managing this syndrome and possibly other related neurological disorders.